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a b s t r a c t
In 518 consecutive STEMI non-diabetic patients, glycated hemoglobin > 6.5% was not
associated with increased short and long term mortality, but was associated with higher
admission glucose values, worse in-hospital glycemic control and a higher incidence of
acute insulin resistance (HOMA index).
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Data on the prognostic role of glycated hemoglobin (HbA1c) in
patients with acute myocardial infarction are still controver-
sial [1–9].
We assessed the prognostic role of HbA1c for short and long
term mortality in 518 consecutive patients with ST elevation
myocardial infarction (STEMI) and without previously known
diabetes. All were treated with mechanical revascularization.
2. Methods
From 1st January 2008 to 30th June 2010, 518 non-diabetic
STEMI patients (within 12 h from symptoms’ onset) were* Corresponding author. Tel.: +39 55 7947518.
E-mail address: lazzeric@libero.it (C. Lazzeri).
0168-8227/$ – see front matter # 2011 Elsevier Ireland Ltd. All rights 
doi:10.1016/j.diabres.2011.09.028admitted to our Intensive Cardiac Care Unit (ICCU) [10–14]. Renal
replacement therapy and mechanical ventilation were used,
when needed [10–13]. After PCI, fasting glucose, insulin [12,13],
C-peptide, HbA1c, troponin I, uric acid, C-reactive protein,
alanine aminotransferase (ALT), aspartate amino transferase
(AST) [15], gammaglutamyl transferase (GGT) [16], NT-pro Brain
Natriuretic Peptide (NT-pro BNP) [13], total cholesterol, trigly-
cerides, HDL, fibrinogen and creatinine were measured.
Glomerular filtration rate (1 ml/min/1.73 m2) was calculated
[17] as well as LDL (nv 60–190). Peak glucose, peak Tn I and nadir
glomerular filtration rate were also measured. Insulin resistance
was defined by the Homeostatic Model Assessment (HOMA).
HOMA was calculated according to the following formula:
{[fasting insulin (microU/ml)]  [fasting glucose (mmol/l)]}/22.5
[27]. Subjects whose values exceeded the sex-specific 75threserved.
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to have insulin resistance (HOMA-IR) [11,12,18].
The study protocol was in accordance with the Declaration of
Helsinki and approved by the local Ethics Committee. Informed
consent was obtained in all patients before enrolment.
3. Statistical analysis
Data are reported as frequencies (percentages) and medians
(95% Confidence Interval – CI) and analyzed by means of x2 (or
Fisher’s exact text, when predicted counts in almost one cell
were less than 5) for categorical variables and Mann–Whitney
U-test for continuous variables (which, at Kolmogorov–
Smirnov normality test, were almost all non-normally
distributed), respectively. In-ICCU mortality was assessed by
logistic regression; a univariant analysis identified parameters
that were significantly associated with outcome and these
were used as candidate variables in a multivariant logistic
regression model. Nagelkerke pseudo-R2 and Hosmer–Leme-
show goodness-of-fit analyses are reported. Since the multi-
variable model was slightly overfitted, due to the low number
of events, the data was further assessed by plotting a receiver
operating characteristic (ROC) curve with each patient’s
estimated probability of death, in order to determine the
discrimination achieved by the area under the curve (AUC).
Long time survival was explored by means of Kaplan–Meier
analysis with respect to HbA1c as a dichotomous variable (Log-
rank test has been reported), as well as, after proportionality of
risk assessment with Cox regression analysis, in both a
univariant and multivariant manner. In this latter analysis,
variables for inclusion were carefully chosen, given the
number of events available, to ensure parsimony of the final
model; non-significant variables were dropped by means of
backward selection. Dichotomous HbA1c was forced into the
analyses. A p value <0.05 was considered statistically
significant (SPSS 13.0; SPSS Inc., Chicago, IL).
4. Results
Patients with HbA1c  6.5% showed higher values of admis-
sion, peak and discharge glucose ( p < 0.001, <0.001 and
<0.001, respectively) and a higher incidence of HOMA
positivity ( p = 0.001) as well as higher values of ESR
( p < 0.001), fibrinogen ( p < 0.001) and triglycerides ( p = 0.001)
and lower values of HDL ( p = 0.018). There were no differences
in short and long-term mortality rates or in the use of devices.
Independent predictors for in-hospital mortality were (multi-Table 1 – Adjusted Cox regression analysis.
HR 95%CI p Wald
Age (1 year step) 1.054 1.018–1.092 0.003 8.828
Discharge LVEF (1% step) 0.951 0.914–0.990 0.014 6.028
Nadir eGFR (1 ml/min/1.73 m2 step) 0.981 0.963–0.999 0.045 4.023
HbA1c >6.5% 0.705 0.213–2.338 0.568 0.326
LVEF: left ventricular ejection fraction; eGFR: estimated glomerular
filtration rate.variate backward logistic regression analysis): admission
glycemia (OR: 3.95, 95%CI: 1.92–8.12, p < 0.001), eGFR (1 ml/
min/1.73 m2 increase) (OR: 0.96, 95%CI: 0.93–0.98, p = 0.002),
peak Tn I (10 ng/ml increase) (OR: 1.03, 95%CI: 1.01–1.06,
p = 0.088). Hosmer and Lemeshow test x2 = 2.58, p = 0. 589;
Nagelkerke R2 = 0.46; area under the ROC curve 93% (95%CI: 88–
99%, p < 0.001). HbA1c was not associated with in-hospital
death (OR: 7.21, 95%CI: 0.75–69.69, p = 0.088). At follow-up
(median of 39.7 months (22.2–57.1)), the Kaplan–Meier survival
curve showed no significant differences between patients with
HbA1c <6.5% and those with 6.5%. Table 1 shows the Cox
regression analysis for long term mortality.
5. Discussion
In patients without a history of diabetes, only small studies on
the prognostic role of HbA1c with different methods and results
exist [6–9]. In 150 non-diabetic patients with MI, mortality rate
and the risk of cardiogenic shock increased with HbA1c [6]. In a
high-risk MI population [8] HbA1c was a risk marker of death at
follow-up in patients without a history of diabetes and not in
diabetic patients. In a small group of MI patients (diabetic and
non-diabetic) treated with thrombolysis [7], there were signifi-
cant relationships between admission glucose, HbA1c level and
mortality at follow-up. Conversely, in 504 unselected, consecu-
tive non-diabetic STEMI patients submitted to PCI, hyperglyce-
mia (not glycated hemoglobin) was a predictor of 30-day
outcome [9]. The main finding of our investigation is that
HbA1c values were not related to mortality, short and long term,
in consecutive STEMI patients without previously known
diabetes, who were submitted to mechanical revascularization.
In our investigation, patients with HbA1c levels higher than
6.5% did not show a higher infarct size (as indicated by Tn I and
left ventricular ejection fraction) or a more critically illness (as
inferred by the use of devices). Discrepancies with previous
papers are mainly related to number consistency [6], population
selection criteria [7] and type of revascularization [9]. Different
from previous studies [6–9], we observed for the first time that
higher HbA1c values helps in identifying a subset of patients
who, in the early phase of STEMI, show an abnormal glucose
response to stress as indicated by higher values of glucose,
worse glycemic control during ICCU stay (peak glycemia) and a
higher incidence of acute insulin resistance (HOMA index). All
these factors have been associated with increased risk of early
death by others [19] and us [10–12,18,20].
Patients with HbA1c > 6.5% also showed a increased
inflammatory activation (increased values of fibrinogen and
ESR), suggesting a link between acute glucose dysmetabolism
and inflammation in the early phase of STEMI [19,20].
In conclusion, though increased values of HbA1c are not
associated with a worse prognosis, non-diabetic STEMI
patients with HbA1c > 6.5% may merit closer attention to
in-hospital glucose management, since they exhibit an
abnormal glucose response to stress.
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